Viewing Study NCT01208051

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:44 PM
Ignite Modification Date: 2026-02-23 @ 8:08 PM
Study NCT ID: NCT01208051
Status: COMPLETED
Last Update Posted: 2021-07-15
First Post: 2010-09-22
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer
Sponsor: National Cancer Institute (NCI)
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Refractory Differentiated Thyroid Gland Carcinoma View
None Refractory Thyroid Gland Follicular Carcinoma View
None Refractory Thyroid Gland Hurthle Cell Carcinoma View
None Refractory Thyroid Gland Papillary Carcinoma View
None Unresectable Thyroid Gland Carcinoma View
Keywords: